Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 5, 2018 (9 years ago)

Decitabine for Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed impurities/degradation specifications: Failure to water content and impurity

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Decitabine for Injection, 50mg per vial, Rx only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-285-37

Affected NDC 69097-0285-37

Compare with the code on your package — it is the most precise check available.

Drug: Decitabine

Recalling firm
InvaGen Pharmaceuticals, Inc.
NDC code
69097-285-37
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0698-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Decitabine recalls

See all
Class II · Moderate risk

Decitabine for Injection 50mg per vial

CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-361-40 D-0582-2024

Other recalls by InvaGen Pharmaceuticals, Inc.

All 2018 recalls
Class III · Low risk

Gabapentin Tablets USP

Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.

Terminated Impurity / degradation InvaGen Pharmaceuticals, Inc. NDC 76282-405-05 D-1272-2020